Nuformix PLC (LSE:NFX, FRA:1RT) (LSE:NFX, FRA:1RT) chief executive Dr Anne Brindley joins Proactive to explain the significance of signing an exclusive global licensing agreement for NXP001, an oncology drug candidate.
The company has licensed NXP001 to a privately owned company, Oxilio Ltd, which will research, develop and commercialise NXP001 globally for oncology indications.
Brindley explains how the company is delighted as the deal is a major step forward as it validates the Nuformix technology and intellectual property, and also endorses the strategy of repurposing drugs and licensing at an early stage.
Brindley also explains her decision to depart the company in January and the company's replacement plans for the CEO position.